NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Novo Nordisk A/S (CO: NOVO-B)

 
NOVO-B Technical Analysis
5
As on 4th Feb 2026 NOVO-B STOCK Price closed @ 304.65 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 479.44 & Strong Sell for SHORT-TERM with Stoploss of 652.91 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

NOVO-BSTOCK Price

Open 302.00 Change Price %
High 314.50 1 Day -63.15 -17.17
Low 296.00 1 Week -92.40 -23.27
Close 304.65 1 Month -3.50 -1.14
Volume 35894116 1 Year -442.95 -59.25
52 Week High 790.30 | 52 Week Low 287.00
 
CO Denmark Most Active Stocks
NOVO-B 304.65 -17.17%
SAS 0.01 0.00%
CONFRZ 0.02 0.00%
VWS 193.15 -2.08%
VJBA 7.33 0.41%
AMBU-B 87.85 5.59%
ALMB 17.30 -0.86%
ORSTED 141.60 -0.84%
DANSKE 332.30 0.36%
TRYG 157.00 1.29%
 
CO Denmark Top Gainers Stocks
HYDRCT 0.60 46.34%
SHAPE 5.03 30.65%
HYPE 3.66 22.00%
DKIEEU 249.00 15.81%
DONKEY 7.10 11.81%
SAME 1.45 10.69%
SAME 1.45 10.69%
ASTRLS 1.15 8.49%
KLEE-B 4400.00 8.37%
MONSO 0.14 7.69%
 
CO Denmark Top Losers Stocks
VALUER 0.25 -21.88%
BLVIS-A 0.40 -18.37%
NOVO-B 304.65 -17.17%
SEIESCP 320.50 -15.61%
MDUNDO 3.00 -13.79%
DNORD 249.00 -12.88%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
 
 
NOVO-B
Daily Charts
NOVO-B
Intraday Charts
Whats New @
Bazaartrend
NOVO-B
Free Analysis
 
NOVO-B Important Levels Intraday
RESISTANCE340.30
RESISTANCE328.87
RESISTANCE321.80
RESISTANCE314.73
SUPPORT294.57
SUPPORT287.50
SUPPORT280.43
SUPPORT269.00
 
NOVO-B Forecast February 2026
4th UP Forecast828.99
3rd UP Forecast660.83
2nd UP Forecast556.89
1st UP Forecast452.94
1st DOWN Forecast156.36
2nd DOWN Forecast52.41
3rd DOWN Forecast-51.53
4th DOWN Forecast-219.69
 
NOVO-B Weekly Forecast
4th UP Forecast375.95
3rd UP Forecast353.08
2nd UP Forecast338.95
1st UP Forecast324.82
1st DOWN Forecast284.49
2nd DOWN Forecast270.35
3rd DOWN Forecast256.22
4th DOWN Forecast233.35
 
NOVO-B Forecast2026
4th UP Forecast1328.27
3rd UP Forecast999.99
2nd UP Forecast797.07
1st UP Forecast594.15
1st DOWN Forecast15.15
2nd DOWN Forecast-187.77
3rd DOWN Forecast-390.69
4th DOWN Forecast-718.97
 
 
NOVO-B Other Details
Segment EQ
Market Capital 1565371138048.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
NOVO-B Address
NOVO-B
 
NOVO-B Latest News
 
Your Comments and Response on Novo Nordisk A/S
 
NOVO-B Business Profile
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Address: Novo Allé 1, Bagsvaerd, Denmark, 2880
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service